BioSpace News Archive

Thermo Fisher Scientific today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.

Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release.

Ultromics’ EchoGo® Heart Failure, an AI solution for echocardiography with the potential to revolutionize the diagnosis of heart failure with preserved ejection fraction (HFpEF), has received US Food and Drug Administration (FDA) clearance.

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced positive results for HER2X® in a range of clinical scenarios, demonstrating the test’s reliability.

The international iReceptor Plus Project unveiled an updated version of the iReceptor Plus Platform, which facilitates the sharing and analyses of antibody and T-cell receptor sequencing data, at the consortium’s meeting which took place on November 28–30, 2022, in Paris.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative at Boston Children’s Hospital.

At the 2022 San Antonio Breast Cancer Symposium, Agendia, Inc., a leader in breast cancer gene expression profiling, will present data demonstrating its proprietary signatures fulfill a critical unmet need for precise, proactive treatment planning for premenopausal women with early-stage breast cancer.

Activ Surgical, a digital surgery pioneer, today announced that it is has received CE Mark approval for its ActivSight™ Intelligent Light (“ActivSight”).

The Cystic Fibrosis Foundation announced that Irena Barisic has been appointed the next Executive Vice President, Chief Operating and Financial Officer.

Systems Oncology today announced they will be presenting positive preclinical data on the company’s next generation estrogen receptor positive drug candidate, SERA2 (Selective Estrogen Receptor Activator).